UBS upgraded UiPath (PATH) to Neutral from Sell with a price target of $17, up from $10, as the analyst resumed coverage of the stock. The outlook is “still mixed,” but near-term GenAI risk fears appear “overdone,” the analyst tells investors.
Claim 30% Off TipRanks
New trading tool for PATH bullsPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PATH:
- Mixed options sentiment in UiPath with shares up 2.23%
- Private Markets: AI model startup Reflection AI raises $2B
- Unusually active option classes on open October 10th
- UiPath’s Strategic Partnerships and AI Adoption: Balancing Growth Opportunities with Uncertainties
- Unusually active option classes on open October 6th